AbbVie Inc (ABBV)vsMedpace Holdings Inc (MEDP)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
MEDP
Medpace Holdings Inc
$418.66
+1.23%
HEALTHCARE · Cap: $11.81B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 2184% more annual revenue ($61.16B vs $2.68B). MEDP leads profitability with a 17.2% profit margin vs 6.9%. ABBV appears more attractively valued with a PEG of 0.48. MEDP earns a higher WallStSmart Score of 66/100 (B-).
ABBV
Buy63
out of 100
Grade: C+
MEDP
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Margin of Safety
-5.3%
Fair Value
$402.51
Current Price
$418.66
$16.15 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Every $100 of equity generates 77 in profit
Strong operational efficiency at 20.0%
Revenue surging 26.5% year-over-year
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Moderate valuation
Expensive relative to growth rate
Trading at 25.9x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : MEDP
The strongest argument for MEDP centers on Return on Equity, Operating Margin, Revenue Growth. Profitability is solid with margins at 17.2% and operating margin at 20.0%. Revenue growth of 26.5% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : MEDP
The primary concerns for MEDP are P/E Ratio, PEG Ratio, Price/Book.
Key Dynamics to Monitor
ABBV profiles as a value stock while MEDP is a growth play — different risk/reward profiles.
MEDP carries more volatility with a beta of 1.39 — expect wider price swings.
MEDP is growing revenue faster at 26.5% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
MEDP scores higher overall (66/100 vs 63/100), backed by strong 17.2% margins and 26.5% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Medpace Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company is headquartered in Cincinnati, Ohio.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?